MedDataX Logo

Prognostic Significance of the Baroreflex Sensitivity Changes After Acute Ischemic Stroke

NCT ID: NCT00422474

Last Updated: 2008-07-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After acute stroke, baroreflex sensitivity (BRS) is impaired. This impaired acute stage BRS has been reported to be predictive of worsen outcome years after stroke in general. However, it is not very clear if the impaired acute stroke BRS would actually persist months after the acute stage. It is also not clear that such change, if any, would correlate with the functional outcome or prognosis after stroke.

The trial is to investigate the longitudinal time course of BRS after ischemic stroke up to the 6th month post stroke and to see if there is any correlation of the changes in BRS with the functional outcome parameters using NIHSS and mRS scores throughout this period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrovascular Accident Baroreflexes Autonomic Nervous System Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ischemic stroke Baroreflex sensitivity Prognosis Cardiovascular autonomic regulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Baroreflex sensitivity can be done within 72 hours of onset of acute ischemic stroke
* 50-80 years old
* Must have either brain CT or brain MRI done

Exclusion Criteria

* NIHSS score \> 10
* Patient could not cooperate
* Unstable vital sign
* Atrial fibrillation
* Transient ischemic attack patient
* Diabetic patient
* Impaired renal function (Cr \> 2.26 mg/dl)
* Unstable angina, acute myocardiac infarction, cardiomyopathy patients
* Patient who has known autonomic dysfunction
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Far Eastern Memorial Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Far Eastern Memorial Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Siupak Lee, M.D.

Role: PRINCIPAL_INVESTIGATOR

Far Eastern Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Far Eastern Memorial Hospital

Banqiao District, Taipei, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Siupak Lee, M.D.

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Siupak Lee, M.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FEMH-95-C-012

Identifier Type: -

Identifier Source: org_study_id